Greenwich Biosciences, Inc. is the US subsidiary of GW Pharmaceuticals plc. For general corporate information, please click here.
May 6, 2019
Greenwich Biosciences Reports Positive Phase 3 Pivotal Trial Results for EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated With Tuberous Sclerosis Complex
May 2, 2019
Greenwich Biosciences to Present Data on FDA-approved EPIDIOLEX (cannabidiol) Oral Solution CV at the 2019 American Academy of Neurology Annual Meeting
Nov 27, 2018
Company Announces Results from Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) Oral Solution CV in Patients with Dravet Syndrome
Nov 19, 2018
Greenwich Biosciences to Present New Data on FDA-approved EPIDIOLEX® (cannabidiol) Oral Solution CV at the American Epilepsy Society Annual Meeting
Nov 1, 2018
EPIDIOLEX® (cannabidiol) Oral Solution – the First FDA-approved Plant-derived Cannabinoid Medicine – Now Available by Prescription in the U.S.